Notizia - Recent Pharma, Healthcare and Biotech Happenings

Sage Therapeutics seeking out to save flunked depression drug  Sage Therapeutics has strategized on how to come back from the phase 3 failure of SAGE-217 in major depressive disorder. The plan focuses on three short-term studies Sage contemplates that may enable it to bring the GABA receptor positive allosteric modulator to market in multiple indications. SAGE-217, aka zuranolone, failed a phase 3 trial late last year that made Sage halt on other studies as it tried to seek out a path forward for the asset. After having a meeting with the FDA, Sage has planned out an R&D strategy that lies somewhere between the best- and worst-case scenarios that have p...